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Human Amniotic Fluid Stem Cells Do Not Differentiate Into 
Dopamine Neurons In Vitro or After Transplantation In Vivo
Angela E. Donaldson, Jingli Cai, Ming Yang, and Lorraine Iacovitti
Although embryonic stem (ES) cells can generate dopamine (DA) neurons that are potentially useful as a cell 
replacement therapy in Parkinson’s disease (PD), associated ethical and practical concerns remain major stum-
bling blocks to their eventual use in humans. In this study, we examined human amniotic fl uid stem (hAFS) 
cells derived from routine amniocenteses for their potential to give rise to DA neurons in vitro and following 
transplantation into the 6-hydroxydopamine-lesioned rat brain. We show that undifferentiated hAFS cells con-
stitutively expressed mRNAs and proteins typical of stem cells but also cell derivatives of all three germ layers, 
including neural progenitors/neurons (nestin, β-tubulin III, neurofi lament). Additionally, these cells expressed 
mRNAs of an immature DA phenotype (Lmx1a, Pitx-3, Nurr1, Aldh1a1) but not the corresponding proteins. 
Importantly, treatment with DA differentiation factors using a variety of protocols did not further promote the 
development of fully differentiated DA neurons from hAFS cells. Thus, Lmx1a, Aldh1a1, AADC, TH, and DAT 
proteins were not detected in hAFS cells in culture or after transplantation into the PD rat brain. Moreover, by 
3 weeks after implantation, there were no surviving AFS cells in the graft, likely as a result of an acute immu-
norejection response, as evidenced by the abundant presence of CD11+ macrophage/microglia and reactive 
GFAP+ astrocytes in the host brain. Taken together, these results suggest that further studies will be needed to 
improve differentiation procedures in culture and to prolong cell survival in vivo if hAFS cells are to be useful 
as replacement cells in PD.
Introduction
Over the last two decades, there has been intense focus on the potential use of stem cells to replace dead or dying 
neurons in neurodegenerative diseases such as Parkinson’s 
disease (PD). Toward this end, stem cells from a variety of 
embryonic and adult sources have been studied in vitro and 
in vivo using a host of differentiation protocols (for review, 
refs. 1,2). To date, partial success has been achieved. While 
adult human bone marrow stromal stem cells (hMSCs) are 
capable of acquiring some dopaminergic traits, they do not 
fully trans-differentiate into dopamine (DA) neurons nor 
do they survive long term transplantation into the brain 
[3]. Greater success has instead been achieved using human 
embryonic stem (hES) cells that can be differentiated into 
neurons of a DA phenotype in vitro and in vivo, and which 
can ameliorate motor defi cits after transplantation into an 
animal model of PD [4–14].
However, ongoing legal, ethical, and practical issues 
associated with ES cells remain major stumbling blocks to 
their eventual use in humans. Consequently, researchers 
continue to search for more practical sources of stem cells 
in humans. One such alternative source that has received 
much interest of late is human amniotic fl uid collected 
during routine amniocenteses. Amniotic fl uid contains a 
variety of cell types derived from both fetal and amnion tis-
sues, ~1% of which are believed to be amniotic fl uid stem 
(AFS) cells [15,16]. Thus, it was of great interest when Atala 
and colleagues [17] reported recently that they had suc-
cessfully established human stem cell lines from amniotic 
fl uid (hAFS). These hAFS cells were capable of unlimited 
self-renewal and differentiation into derivatives of all three 
germ layers in culture, sharing overlapping but not identi-
cal properties with pluripotent hES cells [17]. Of particular 
signifi cance, was their ability to express traits of a neural 
lineage (i.e., nestin and β-tubulin III) in culture and after 
transplantation into the brain. Unlike their hES cell counter-
parts, hAFS cells reportedly showed no sign of tumorigenic-
ity in vivo. Thus, hAFS cell lines could provide an abundant, 
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~1 × 106 of undifferentiated (N = 4) or semi-differentiated 
[cells treated with bFGF in Protocol A (N = 2) or neuro-
spheres generated in Protocol B (N = 8)] hAFS cells, depos-
ited at three stereotaxic levels (AP: +1.2mm, ML: −2.7 mm, 
DV: −5.4 mm, −4.9 mm and −4.2 mm) in the striatum on 
the side ipsilateral to the 6-OHDA lesion as described previ-
ously [13]. All transplant recipients received cyclosporine A 
(15 mg/kg, i.p.) daily, beginning 1–2 days before transplan-
tation. Animals with hAFS cell transplants were sacrifi ced at 
3 days, 1 and 3 weeks and brains sectioned for immunocy-
tochemical analysis.
Immunocytochemistry
Cultures were rinsed twice in PBS, fi xed with 4% para-
formaldehyde and immunocytochemically stained (details 
described in 14). Antibodies used were: mouse monoclonal 
anti-Nestin (Chemicon 1:250), rabbit polyclonal anti-homeobox 
transcription factor 1 alpha (Lmx1; gift from Dr. M. German 
1:1,000), mouse monoclonal anti-β-tubulin III (R&D Systems 
1:400), goat polyclonal anti-retinaldehyde dehydrogenase 
(Aldh1a1) (Novus Biologicals 1:500), rabbit polyclonal anti-
tyrosine hydroxylase (TH) (Pel-Freez 1:150), sheep polyclonal 
anti-TH (Abcam 1:1000), rabbit polyclonal anti-glial fi brillary 
acidic protein (GFAP) (Chemicon 1:1000), rabbit polyclonal anti-
aromatic l-amino acid decarboxylase (AADC) (Protos Biotech 
1:50) mouse monoclonal anti-dopamine transporter (DAT) 
(Chemicon 1:50). All secondary antibodies were Alexa Fluor 
antibodies from Invitrogen; donkey anti-rabbit 594, 1:300; don-
key anti-rabbit 488, 1:300; donkey anti-mouse 594, 1:300; don-
key anti-mouse 488, 1:300.Cultures were mounted in ProLong 
Gold antifade reagent with DAPI (Invitrogen). Stained cells 
were counted in representative fi elds (N = 5) on duplicate 
slides and expressed as a percentage of the total cells.
For immunocytochemical staining in transplantation 
experiments, rats were perfused with 500 mL of cold (4°C) 
periodate-lysine-paraformaldehyde (4%). Brains sections 
were cut at 30 μm on a freezing microtome and processed 
for immunocytochemistry as described previously [6,14]. 
Antibodies were used as above except for the following 
differences: (β-tubulin III; 1:200), HNA (1:40); GFAP from 
Chemicon (1:200) and mouse monoclonal anti-CD11 from 
BD Biosciences (1:25). Brain sections were analyzed along the 
length of the graft using a Nikon-Scanalytics Image System 
or a Zeiss LSM510 Confocal Image System.
RNA isolation and cDNA synthesis
Total RNA was isolated directly from freshly col-
lected hAFS neurospheres and H9 StgIV cells with TRIzol 
(Invitrogen), a modifi cation of the guanidine isothiocyanate-
phenol-chloroform extraction method. cDNA was synthe-
sized by using 100 ng total RNA in a 20 μL reaction with 
Superscript III (Invitrogen) and oligo (dT)12–18 (Invitrogen). 
One microliter of RNase H (Invitrogen) was added to each 
reaction tube, and the tubes were incubated for 20 min at 
37°C before proceeding to polymerase chain reaction (PCR).
PCR amplifi cation
A 0.5 μL cDNA template was used in a 20 μL reaction 
 volume with the PCR master mix (Promega).The cycling 
parameters were: 94°C, 1 min; 55°C, 1 min; 72°C, 1min, for 
nontumor-forming source of human stem cells free of ethi-
cal dilemma that could be used in cell replacement therapies 
for diseases like PD. Therefore, in this study, we investigated 
whether cells derived from hAFS cell lines could indeed be 
differentiated into neurons, particularly those that express 
traits of a DA phenotype either in vitro or after transplanta-
tion in vivo into PD rats.
Materials and Methods
Cell propagation/differentiation in culture
Cells of the AFS-A1 (Passage 15) and AFS-H1 (Passage 18) 
cells lines were generously supplied by A. Atala (Wake 
Forest University, NC). Human AFS cells were cultured on 
polystyrene (Petri) dishes in α-MEM medium (Invitrogen) 
containing 18% Chang’s Medium B, 2% Chang’s Medium 
C (Irvine Scientifi c), ES-qualifi ed 15% FBS (Invitrogen), 1% 
L-glutamine and 1% Penicillin/Streptomycin (Invitrogen) at 
37°C with 5% CO2 atmosphere. Cells were passaged at 70% 
confl uence at a dilution of 1:4 to 1:6 and used for experiments 
at Passage 15–21 for A1 cells and Passage 18–27 for H1 cells. 
For differentiation protocols, cells were grown either accord-
ing to Protocol A in defi ned serum-free (DM) media plus 20 
ng/mL of basic fi broblast growth factor (bFGF) for 1 week 
followed by 1 week in 10 ng/mL aFGF, 200 nM TPA, 20 μM 
DA, 0.25 mM IBMX plus 50 μM forskolin; or Protocol B as 
described in Results. Essentially, neurosphere-like clusters 
were generated from 5 × 105 cells grown in suspension in 
DM + Noggin (200 ng/mL) and maintained for 5–7 days (as 
described previously in ref. 6). Cells were gently lifted with 
a P1000 pipette and seeded in Ultra-low attachment dishes 
(Corning). In addition, cells were plated at a high density 
(100,000–150,000 cells in 25 μL seeded droplet) on chamber 
slide wells coated with polyornithine, 100ng/cm2 human 
collagen IV, 10 ng/mL laminin or 5 μg/mL human plasma 
fi bronectin and incubated with a variety of other differenti-
ation protocols (Table 2).
6-OHDA lesions
Animals were maintained in accord with the Offi ce 
of Animal Resources at Thomas Jefferson University and 
IACUC policies. As described previously [14,18], 12 Fischer 
344 rats (Taconic) were made Parkinsonian for these stud-
ies. Briefl y, rats were anesthetized with sodium pentobarbi-
tal [30 mg/kg, intraperitoneally (i.p.)], placed in a stereotaxic 
apparatus (Kopf Instruments) and a 26-gauge Hamilton 
syringe containing 6-OHDA (Sigma; 20 μg/mL in 4 μL phos-
phate-buffered saline (PBS) containing 0.2 mg/mL ascor-
bate) was lowered into the right median forebrain bundle 
(AP: −4.4mm, ML: −1.2mm, DV: −7.8 mm from bregma). 
The 6-OHDA solution was gradually injected at a rate of 
1 μL/min. All lesions were verifi ed 3 and 6 weeks later by 
assessment of rotational behavior in an automated rotome-
ter system (Columbus Instruments) following amphetamine 
challenge (5 mg/kg, i.p.). Only rats with consistent and sta-
ble lesions (>10 ipsilateral turns/min on multiple tests) were 
used for transplantation studies.
Transplantation procedures
Animals with verifi able lesions (>10 ipsilateral turns/
min) were implanted with a total of 10 μL of PBS containing 
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due to the presence of potentially toxic substances like for-
skolin. Using the hES differentiation protocol developed in 
this laboratory (Protocol B) (Fig.1B), hAFS cells were fi rst 
incubated with 200 ng/mL noggin for 4 days to promote the 
formation of clusters of neural progenitors. This stage was 
next followed by a 1 week expansion phase during which 
cells were propagated as neurospheres in suspension before 
plating as dissociated cells. Unlike hES cells, hAFS cells did 
not readily form compact spheres nor did they require sub-
cloning, suggesting that the nestin+ cells in these spheres 
were not dividing as robustly as in hES cell cultures. Finally, 
when hAFS neurospheres were dissociated into single cells 
for further differentiation in adherent cultures, we found 
poor attachment to substrates (polyornithine, laminin, fi bro-
nectin, collagen type IV) previously used to adhere other 
types of stem cells [3,6,14,17]. Adherence of a small num-
ber of dissociated neurosphere (Protocol B) hAFS cells only 
when polyornithine-coated dishes were also treated with 
fi bronectin.
30 cycles. The PCR cycles were preceded by an initial dena-
turation of 3 min at 94°C and followed by a fi nal extension 
of 10 min at 72°C (details in ref. 14) (primers are listed in 
Table 1).
Results
Undifferentiated hAFS cells were propagated as described 
previously [17]. We fi rst tested various differentiation proto-
cols (see Table 2 for complete list), beginning with several 
used successfully to differentiate DA neurons either from 
hMSCs [3] or hES cells [6] in our laboratory. Undifferentiated 
hAFS cells, grown according to the mesenchymal protocol 
(Protocol A) (Fig. 1A), were fed a defi ned media contain-
ing 20 ng/mL of bFGF for 1 week followed by an additional 
week in the DA differentiation cocktail (10 ng/mL aFGF, 200 
nM TPA, 20 μM DA, 0.25 mM IBMX plus 50 μM forskolin) as 
described previously [3,18,19]. This media often produced a 
high level of cell death after several days in culture, possibly 
Table 1. Primers
Gene name
Accession 
no. Primer sequence
Product 
size (bp)
Oct4 BC117435 CTTGCTGCAGAAGTGGGTGGAGGAA 169
CTGCAGTGTGGGTTTCGGGCA
Sox2 NM_003106 ATGCACCGCTACGACGTGA 437
CTTTTGCACCCCTCCCATTT
Nestin NM_006617 CAGCGTTGGAACAGAGGTTGG 389
TGGCACAGGTGTCTCAAGGGTAG
Vimentin NM_003380 GACACTATTGGCCGCCTGCAGGATGAG 418
CTGCAGAAAGGCACTTGAAAGC
βIIItubulin NM_006086 GAACAGCACGGCCATCCAGG 244
CTTGGGGCCCTGGGCCTCCGA
NEFH NM_021076 TGCGGCGCCACCACCAG 452
GGCGGCCATCTCCCACTTG
GFAP NM_002055 GTGGGCAGGTGGGAGCTTGATTCT 388
CTGGGGCGGCCTGGTATGACA
AFP NM_001134 AAATACATCCAGGAGAGCCA 417
CTGAGCTTGGCACAGATCCT
FN NM_212482 TGTTATGGAGGAAGCCGAGGTTTT 150
CCCGATGCAGGTACAGTCCCAGAT
Lmx1a AY078391 CTCAATTTAGTGTATGAAGAGG 372
CTACATTCTCTTGGCTGGAC
Aldh1a1 NM_000689 CTGAAATGTGACCCCCAAGT 280
TGACAAGCAGACATGACATCC
Pitx3 NM_005029 GGACTAGGCCCTACACACAGA 151
TCCGCGCACGTTTATTTC
Nurr1 NM_006186 GGCTGAAGCCATGCCTTGT 150
GTGAGGTCCATGCTAAACTTGACA
Girk2 NM_002240 CAACAATGGCCAAGCTGACA 150
TCCGATCTCGGCTGATGTG
AADC NM_000790 GGGACCACAACATGCTGCTC 145
CCACTCCATTCAGAAGGTGCC
DAT NM_001044 TCCATCAACTCCCTGACGAGCTTC 500
CTGGGCCGCTGCCCGGTCATCTGC
TH NM_199292 TCATCACCTGGTCACCAAGTT 125
GGTCGCCGTGCCTGTACT
GAPDH NM_002046 ACAGTCAGCCGCATCTTCTT 259
  GACAAGCTTCCCGTTCTCAG  
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regulated inwardly rectifying potassium channel (Girk2)] by 
PCR. We found that undifferentiated hAFS cells expressed 
not only stem cell transcripts, but also markers of the three 
germ layers, including those associated with an endodermal 
(AFP), mesodermal (FN) and neurectodermal lineage (nes-
tin, β-tubulin III, human NEFH). Of particular interest was 
expression of mRNAs normally associated with more differ-
entiated neuronal phenotypes (Fig. 2). Consequently, early 
markers of a DA phenotype, such as Lmx1a and Aldh1a1, 
To assess the degree of differentiation achieved by these 
cells at various stages in these treatment protocols, we next 
examined the expression of stem cell (Oct4, Sox2), neural 
progenitor (nestin, vimentin), neural [β-tubulin III, neuro-
fi lament (NEFP)] glial (GFAP), endodermal [α-fetoprotein 
(AFP)] and mesodermal (fi bronectin:FN) markers as well as 
specifi c markers of the DA system, including the DA tran-
scription factors (Lmx1a, Nurr1, Pitx3), enzymes (Aldh1a1, 
AADC, TH), transporters (DAT) and channels [G-protein 
Table 2. Differentiation of Amniotic Fluid Stem (AFS) Cells Using Various Treatment Protocols
Treatment Nestin Lmx1a Sox2 Aldh1a1 βtubIII TH GFAP
Undifferentiated AFS Cells 2+ – – 1+ 1+ – –
Defi ned Media – 7 div 2–3+ – – 1+ 1+ – –
Protocol A        
DM + bFGF (20 ng/mL) – 7 div 4+ – – 2+ 1+ – –
DM + aFGF + DA + TPA + IBMX + Forskalin – 7 div 2+ – – 1+ 3+ – –
 *High cell death        
Protocol B        
DM + Noggin (200 ng/mL) – 5–7 div        
Lift as neurospheres and seed in ultra-low attachment dish        
 Neurocult proliferation media – 7 div 3–4+       
Plate on P-Orn/fi bronectin and diff in:        
 DM + cAMP (1μM) + Ascorbate – 2 div        
 DM + cAMP (500μM) + Ascorbate – 2 div 2+ – – – 1+ – –
DM + bFGF (20 ng/mL) + Noggin (200 ng/mL) – 7 div 4+ – – 2+ 1+ – –
DM + bFGF (20 ng/mL) – 7 div        
DM + SHH (200 ng/mL) + FGF8 (100 ng/mL) + bFGF 
(20 ng/mL) – 7 div
       
 *Cell death at 5 div        
NB media + B27 + SHH (250 ng/mL) + FGF8 (100 ng/mL) 
+ bFGF (50 ng/mL) – 7 div
3–4+ – – – 1+ – –
DM + B27 + BDNF (25 ng/mL) + forskolin (15 μM) + 
DA(10 μM) – 7 div
2+       
 *No change in morphology        
DM + B27 + Wnt1 (10 ng/mL) + bFGF (20 ng/mL) – 7 div 4+ – – – 1+ –  
DM + B27 + ascorbate (200 μM) + cAMP (500 μM) 2+ – – – – –  
 *High cell death        
DM + aFGF + DA + TPA + IBMX + Forskalin – 7 div        
 *Cells died within 5 div        
DM + bFGF (20 ng/mL) + Wnt5A (100 ng/mL) – 7 div 4+ – – – 1+ –  
 *Nestin + FoxA2 double-labeled cells (1–2+)        
DM + substantia nigra conditioned media (1:1) – 7 div 2+ – – – – –  
 *No change in cells        
DM + glial conditioned media (1:1) – 7 div 2+ – – – – –  
 *No change in cells        
DM + H9 stg 5 conditioned media (1:1)        
 *Cells died within 4–5 days        
DM + MEF conditioned media (1:1) – 7 div 2+ – – – – –  
 *No change in cells        
AFS cells were stained for the presence of cell type specifi c markers after differentiation using a particular treatment protocol. For 
cultures treated with conditioned media, defi ned media was incubated for 3 days on cultures of P1 rat glia, E14 rat substantia nigra, 
mouse embryonic fi broblasts (MEF from specialty media), and stage V hES cells as described in ref. 6. Cultures of viable cells were 
stained with the markers listed and evaluated for the intensity of staining as follows: none (–), lightly (1+), moderately (2–3+), or darkly 
(4+) stained cells. 
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DA-specifying gene Lmx1a were down regulated (Fig. 2). 
However, hAFS neurospheres generated in Protocol B con-
tinued to express Lmx1a as well as several other transcripts 
associated with a more differentiated DA phenotype (i.e., 
Pitx3, Nurr1 and Girk2; Fig. 2).
Next, sister cultures were stained with antibodies to 
many of these cell types and DA-specifi c markers. Similar 
were readily detected by reverse transcription (RT)-PCR 
while more mature DA markers (AADC, TH, DAT) were not. 
When hAFS cells were further differentiated by either pro-
tocol, we continued to see many of the same transcripts as 
in the undifferentiated state, with the exception of the dis-
appearance of the endodermal marker AFP (Fig. 2). In addi-
tion, with Protocol A, the stem cell marker Oct 4 and the 
Propagation of 
undifferentiated AFS cells
Propagation of 
undifferentiated AFS cells
Culture
Days
0
Chang’s Medium DMbFGF DMaFGFDATPAIBMXForskolin
Chang’s Medium DMNoggin
Neurocult NS-A
Proliferation Medium
7 14
Culture
Days
0 4 11
A Protocol A
B Protocol B
Nstn/Dapi Nstn/Dapi
Nstn/Dapi Nstn/Dapi
β-TubIII
Expansion of nestin
positive progenitor cells
Selection of nestin
positive progentior cells
Expansion of progentior
cells as neurospheres
Neuronal differentiation
FIG. 1. Depiction of various treatments used to differentiate human amniotic fl uid stem (hAFS) cells into dopamine (DA) 
neurons in culture. (A) Protocol A was previously used to differentiate DA neurons from human mesenchymal stem cells 
(hMSCs) and was described in detail in ref. 3. (B). Protocol B was previously used to differentiate DA neurons from hES cells 
and was described in ref. 6.
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denervated side. Fully differentiated cells were not used in 
transplantation experiments (i.e., Protocol A) because pro-
cess-bearing neurons do not generally survive harvest and 
implantation. Of the 12 animals that were transplanted, only 
one graft of neurospheres (Protocol B) contained viable hAFS 
cells, as evidenced by the presence of the human nuclear 
antigen marker (HNA) (Fig. 4A), and only at their earliest 
time point examined (3 days after implantation). As shown 
in Fig. 4A, surviving cells exhibited an immature morphol-
ogy, expressing markers of neural progenitors (nestin; Fig. 
4A) and neurons (β-tubulin III) but not DA neuron traits 
(Lmx1a or TH; data not shown). Importantly, when grafts 
of these same cells were examined at 3 weeks after implan-
tation, no hAFS cells remained at the implantation site (note 
the absence of HNA staining in Fig. 4B) nor were HNA+ cells 
found in surrounding brain regions. Residual nestin stain-
ing observed in the vicinity of the graft was instead likely 
due to the presence of host brain progenitors. When these 
brains were further examined for the presence of reactive 
glia and macrophage/microglia, we found copious staining 
for their respective type-specifi c markers, GFAP and CD11 in 
host cells adjacent to the graft site at 3 days (data not shown) 
and 3 weeks (Fig. 4C and D) after implantation.
Discussion
This study has examined hAFS cells as an abundant, 
practical, and ethical source of stem cells to generate neurons 
for cell replacement therapies. In particular, our laboratory 
is interested in the differentiation of hAFS cells into func-
tional DA neurons to replace cells lost in PD. We show here 
that undifferentiated hAFS cells from established cells lines 
[17] constitutively expressed mRNAs and proteins typical of 
stem cells but also cell derivatives of all three germ layers, 
including neural progenitors/neurons (nestin, β-tubulin III, 
NEFH). Additionally, these undifferentiated cells expressed 
specifi c transcripts appropriate to an immature DA pheno-
type (Lmx1a, Pitx-3, Nurr1, Aldh1a1). However, treatment 
of hAFS cells with various DA differentiation factors using 
a number of published protocols did little to advance their 
development into fully differentiated DA neurons. Only 
cells grown as neurospheres and differentiated as described 
in Protocol B exhibited an increase in the expression of some 
DA transcripts. When AFS neurospheres were transplanted 
in vivo, cells did not survive more than several days fol-
lowing their transplantation into the PD rat brain, likely 
due to an intense immunorejection response in host tissue. 
Transplanted cells that did survive in the short term, how-
ever, did not express detectable levels of any of DA proteins 
(Lmx1a, Aldh1a1, AADC, TH, DAT).
The fact that hAFS cells, even after incubation with 
known neuron-promoting differentiation factors [3–14,20], 
continued to express transcripts of non-neuronal cell types 
indicates that hAFS cells behave quite differently from other 
pluripotent stem cell sources. Thus, hES cells that initially 
express transcripts from all three germ layers, if grown 
under the same conditions used here (Protocol B), will 
proceed down a neural progenitor pathway to selectively 
become neurons [4–14]. Likewise, adult stem cells (hMSCs) 
grown under similar culture conditions (Protocol A) down-
regulate mesenchymal (FN) transcripts with the expression 
of neuronal markers (nestin, β-tubulin III) [3,20]. In con-
trast, in this study, undifferentiated hAFS cells expressed 
to our RT-PCR results, using immunocytochemistry, we 
found that progenitor protein nestin was robustly expressed 
in 20–40% of individual undifferentiated hAFS cells (Fig. 
1A, 1B insets; Table 2). With further differentiation, cells 
changed in morphological shape but continued to express 
nestin. Moreover, the proportion of nestin+ cells increased, 
with the greatest number (>80%) found in semi-differenti-
ated cultures (Protocol A) and in neurospheres (Protocol B) 
(Table 2). In contrast, relatively few (<20%) undifferentiated 
or semi-differentiated hAFS cells expressed the early neuron 
marker β-tubulin III (Fig. 3). The number of β-tubulin III+ 
cells did however increase (40–60%) after the fi nal differen-
tiation step in Protocol A. Because in Protocol B dissociated 
neurosphere cells did not attach well to adherent substrates, 
we could not assess the degree of neuronal differentiation in 
these cultures (Table 2).
When semi-differentiated or fully differentiated cultures 
were further probed for the expression of DA marker pro-
teins, importantly, no positively stained cells were observed 
regardless of their state of differentiation or the protocol 
used (Table 2). Thus, Lmx1a-staining cells were not detected 
by immunocytochemistry in these cultures despite detec-
tion of Lmx1a mRNA in pooled cell cultures. Likewise, nei-
ther Aldh1a1, AADC, TH nor DAT positive staining was 
observed in undifferentiated or differentiated AFS cells 
(Table 2), unlike other stem cell derivatives studied in our 
laboratory [3,6,14,18].
We next sought to determine whether transplantation of 
hAFS cells into the brain would further foster their develop-
ment into DA neurons. Thus, undifferentiated (N = 4) and 
semi-differentiated hAFS cells (cells semi-differentiated 
with bFGF in Protocol A; N = 2 or neurospheres generated 
in Protocol B; N = 8) were transplanted into the striata of 
hemi-lesioned (6-OHDA) immunosuppressed rats on the 
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FIG. 2. RT-PCR analysis of various stages in human amni-
otic fl uid stem (hAFS) cell differentiation. Markers of stem 
cells (Oct4, Sox2), neural progenitors (nestin, vimentin), 
neurons (βIIItubulin, NEFH), glia (GFAP), ectoderm (AFP), 
mesoderm (FN), as well as DA-related markers (Lmx1a, 
Aldh1a1, Pitx3, Nurr1, Girk2, AADC, DAT, TH) were com-
pared in undifferentiated (AFS-undiff) or partially differen-
tiated cells (AFS-semidiff with bFGF according to Protocol A) 
or following neurosphere formation (in Protocol B). Positive 
controls taken from human embryonic stem (hES) cells dif-
ferentiated into DA neurons (as described in ref. 14) were 
also included for AADC and TH as these were not expressed 
in AFS cells.
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there was no immunocytochemical evidence for Lmx1a, 
Aldh1a1, AADC, TH, or DAT in these cells, regardless of their 
differentiation status or their expression of DA mRNAs. The 
reasons for this disparity remain unknown but suggest that 
cells may be trapped in a primitive state, unable to produce 
critical proteins of a differentiated neuronal subtype using 
these treatment protocols. Consistent with this possibility is 
the fact that mature DA phenotypic traits, such as the expres-
sion of the key DA rate-limiting enzyme TH or the second 
enzyme in DA biosynthesis AADC, were never observed 
at either the transcriptional or protein levels in these cells. 
Nonetheless, the DA-associated Girk2 channel [21–23] was 
detected by RT-PCR both in this study and by Atala and col-
leagues who also demonstrated its functionality (i.e., barium 
sensitivity) in culture [17]. As Girk2 expression has also been 
reported in a variety of non-DA neurons [24–26), proof that 
its expression here represents the acquisition of a bona fi de 
DA neuronal trait will require experimental corroboration 
by other methods. Additionally, using different AFS lines 
and a different DA differentiation protocol, Tsai et al. [27] 
transcripts for nestin, β-tubulin III and FN, with no shift in 
the mRNA expression profi le toward a neuronal fate after 
further differentiation in culture. Although differentiated 
hAFS cells acquired a neuronal like appearance and stained 
for neuronal marker proteins, it remains uncertain whether 
these cells can in fact function as neurons.
Further distinguishing the behavior of hAFS cells from 
other stem cell types was their acquisition of DA traits. 
Earlier studies on hMSCs and hES cells demonstrated that 
DA-related markers that were absent in undifferentiated 
cells could be partially or fully induced in vitro and in vivo 
using Protocols A and B, respectively [3,6,14,20]. In contrast, 
in this study, even in the undifferentiated state, hAFS cells 
expressed a number of mRNAs normally associated with 
DA-specifi ed progenitors/neurons but could not be further 
induced to complete their DA differentiation by incubation 
using published protocols (Table 2). Although in Protocol B, 
neurosphere cells did not survive plating and growth on dif-
ferentiation medium in order to assess DA protein expres-
sion, using Protocol A (and other differentiation schemes) 
A B Protocol A
β-Tub III/Dapi Undiff β-Tub III/Dapi Semidiff β-Tub III/Dapi Diff
Protocol AC
FIG. 3. Immunocytochemical localization of β-tubulin III in amniotic fl uid stem (AFS) cells at various stages of differenti-
ation. AFS cells were stained with β-tubulin III antibodies in the undifferentiated (Undiff) state (A) or after semi-differen-
tiation (Semidiff) (B) and full differentiation (Diff) (C) using procedures described in Protocol A (as shown in Fig. 1). While 
many cells express β-tubulin III in all stages, unseen in imaged fi elds are other cells which do not express the neuronal 
marker. Note the change in cell shape as cells become more differentiated.
NSTN&HNA
GFAP&CD11
3 Days 3 Weeks
3 Weeks
LV
3 Weeks
NSTN&HNAA
C GFAP&CD11D
B
FIG. 4. Immunocytochemical localization of phe-
notypic markers at various times after transplan-
tation of amniotic fl uid stem (AFS) neurospheres 
into the striata of 6-OHDA treated rats. Cells were 
double labeled for: nestin and HNA at 3 days (A) 
and nestin and HNA (B) or GFAP and CD11 (C 
and D) at 3 weeks after transplantation. Panel D 
is a higher power view of the graft site shown in 
Panel C. Sections were mounted in ProLong Gold 
antifade reagent with DAPI (Invitrogen) and ana-
lyzed along the length of the graft using a Nikon-
Scanalytics Image System or a Zeiss LSM510 
Confocal Image System. Bars = 100 μM.
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showed that small quantities of DA could be detected in 
the media following KCl-stimulated release. However, they 
did not provide evidence that AFS cells possessed the DA 
synthetic machinery (TH, AADC) to manufacture DA as 
opposed to simply taking up and re-releasing DA found in 
their (serum-containing) media.
Although the initial report describing these hAFS lines 
reported long-term survival of cells after transplanta-
tion into the lateral ventricles of newborn mice [17], in our 
transplantation studies, hAFS cells did not persist in the 
adult PD rat brain. This was likely due to the acute immu-
norejection of cells as evidenced by the copious expression 
of the microglial/macrophage marker CD11 and the reactive 
glial marker GFAP in host cells near the site of transplan-
tation. This rejection response occurred despite the immu-
nosuppression of rats with Cyclosporin A using a regimen 
that has successfully supported the long-term survival of 
other xenotransplanted human stem cells [3,6,14]. Similar 
to our observations, others using the same cell lines, also 
found an intense immunorejection response after hAFS 
transplantation into the immunosuppressed and immuno-
defi cient rat myocardium [28]. Although hAFS cells were 
originally thought to be non-immunogenic because of their 
lack in major histocompatibility complex class II molecules, 
there is now evidence for expression of T-cell co-stimulatory 
molecules (normally found on antigen presenting cells) that 
may contribute to their immunorejection after transplanta-
tion [28]. Possibly, as a result of the relative immaturity of the 
newborn immune system, these molecules are less effective 
thereby allowing the survival of transplanted hAFS cells 
into the perinatal brain [17]). Another possible explanation 
for the rejection of these cells may stem from their hetero-
geneity, with mesodermal derivatives causing an intense 
immune/infl ammatory response in the brain [3]. Of the few 
cells that did survive in the short term after transplantation 
into the brain, there was little evidence of maturation into 
fully differentiated neurons or incorporation into surround-
ing host tissues. A similar lack of neuronal differentiation 
and integration has recently been observed following the 
transplantation of human cord blood into the retina [29].
In sum, our studies have demonstrated that although 
hAFS cells constituitively express a number of traits nor-
mally associated with neural progenitors/immature neu-
rons, they cannot be induced to acquire a fully differentiated 
DA neuronal phenotype in vitro or in vivo. In addition, 
these cells are highly immunogenic, inducing an acute rejec-
tion response after transplantation into the adult immuno-
suppressed rat brain. Taken together, these results suggest 
that further studies will be needed to improve differentia-
tion procedures in culture and to prolong cell survival in 
vivo if hAFS cells are to be useful as replacement cells in PD 
therapy.
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